3-Deacetoxy-7-(alpha-amino-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100), a new semisynthetic cephalosporin. I. Comparative in vitro antibacterial activities of SCE-100 and cephalexin (CEX).
3-Deacetoxy-7(alpha-amino)-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100) has a potent antibacterial activity against Gram-positive and Gram-negative bacteria. The minimum inhibitory concentration of SCE-100 is 0.2 approximately 12.5 mug/ml against Gram-positive bacteria including penicillin G-resistant Staphylococcus aureus and 6.25 approximately 100 mug/ml against Gram-negative bacteria. SCE-100 inhibits clinically isolated strains of penicillin G-resistant S. aureus and ampicillin-resistant Escherichia coli, as well as the corresponding sensitive strains. The activity of SCE-100 is enhanced by decreasing the inoculum size and is only slightly influenced by medium pH, difference of medium composition and the addition of horse serum. SCE-100 has bactericidal activity against S. aureus and E. coli. There is a stepwise development of in vitro bacterial resistance to SCE-100 by serial transfer of organisms into a liquid medium containing SCE-100. Cross resistance was observed between SCE-100 and other tested cephalosporins.
D001419:Bacteria / Q000187:drug effects*; D002437:Cefazolin / Q000494:pharmacology; D002506:Cephalexin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002509:Cephaloridine / Q000494:pharmacology; D002512:Cephalothin / Q000494:pharmacology; D003429:Cross Reactions; D003470:Culture Media; D004755:Enterobacteriaceae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D013997:Time Factors
D003470:Culture Media; D002437:Cefazolin; D002509:Cephaloridine; D002506:Cephalexin; D002512:Cephalothin